- Home
- ARCT vs OCS Comparison
ARCT vs OCS Comparison
Compare ARCT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- OCS
- Stock Information
- Founded
- ARCT 2013
- OCS 2003
- Country
- ARCT United States
- OCS Switzerland
- Employees
- ARCT N/A
- OCS N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- OCS Health Care
- Exchange
- ARCT Nasdaq
- OCS Nasdaq
- Market Cap
- ARCT 602.7M
- OCS 706.3M
- IPO Year
- ARCT N/A
- OCS N/A
- Fundamental
- Price
- ARCT $16.02
- OCS $14.14
- Analyst Decision
- ARCT Strong Buy
- OCS Strong Buy
- Analyst Count
- ARCT 7
- OCS 5
- Target Price
- ARCT $65.00
- OCS $29.20
- AVG Volume (30 Days)
- ARCT 400.2K
- OCS 73.4K
- Earning Date
- ARCT 11-07-2024
- OCS 11-07-2024
- Dividend Yield
- ARCT N/A
- OCS N/A
- EPS Growth
- ARCT N/A
- OCS N/A
- EPS
- ARCT N/A
- OCS N/A
- Revenue
- ARCT $160,399,000.00
- OCS $1,027,571.00
- Revenue This Year
- ARCT $13.02
- OCS $4.38
- Revenue Next Year
- ARCT $5.58
- OCS $905.09
- P/E Ratio
- ARCT N/A
- OCS N/A
- Revenue Growth
- ARCT N/A
- OCS N/A
- 52 Week Low
- ARCT $14.93
- OCS $9.60
- 52 Week High
- ARCT $45.00
- OCS $18.00
- Technical
- Relative Strength Index (RSI)
- ARCT 31.24
- OCS 37.01
- Support Level
- ARCT $18.90
- OCS $16.44
- Resistance Level
- ARCT $21.61
- OCS $18.00
- Average True Range (ATR)
- ARCT 1.15
- OCS 0.68
- MACD
- ARCT -0.07
- OCS -0.46
- Stochastic Oscillator
- ARCT 16.32
- OCS 3.50
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.